Article ISI
ANNALS OF ONCOLOGY  (2020)

Survival of responders to nivolumab (NIVO) plus ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1

Brahmer, J. R.; Ciuleanu, T-E.; Schenker, M.; Audigier-Valette, C.; Zurawski, B.; Linardou, H.; Kim, S-W.; Otterson, G. A.; Salman, P.; De La Mora Jimenez, E.; Lesniewski-Kmak, K.; Ahmed, S.; Albert, I.; Barlesi, F.; Feeney, K.; et. al.